1. Home
  2. RMCF vs HIND Comparison

RMCF vs HIND Comparison

Compare RMCF & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$0.88

Market Cap

14.9M

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

N/A

Current Price

$2.14

Market Cap

15.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RMCF
HIND
Founded
1981
2017
Country
United States
United States
Employees
N/A
18
Industry
Specialty Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
15.2M
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
RMCF
HIND
Price
$0.88
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
135.5K
18.5K
Earning Date
06-16-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$1.75
52 Week High
$2.99
$12.87

Technical Indicators

Market Signals
Indicator
RMCF
HIND
Relative Strength Index (RSI) 18.91 47.34
Support Level N/A $1.99
Resistance Level $1.87 $2.39
Average True Range (ATR) 0.19 0.13
MACD -0.05 -0.01
Stochastic Oscillator 2.27 14.93

Price Performance

Historical Comparison
RMCF
HIND

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: